Provider Education: Understanding Biosimilar Differences and Why It Matters
January 10, 2026 by Maxwell Harrington
Understand the critical differences between biosimilars and generics, why provider education is lagging, and how to confidently prescribe biosimilars to improve patient access and reduce costs.
Biologic Patent Protection: When Biosimilars Can Enter the U.S. Market
December 26, 2025 by Maxwell Harrington
Biologic patent protection in the U.S. grants 12 years of exclusivity before biosimilars can enter the market. Complex regulations, patent thickets, and high development costs delay competition, keeping prices high and patients paying more than they should.